Abstract
Prostate cancer is the most common cancer among men with 27 % of all male cancer cases. While prostate cancer is uncommon in young males, its incidence increases with age, affecting 1 in 43 men aged 50–59; 1 in 16 men aged 60–69; and 1 in 9 men aged >70. The life-time risk of developing prostate cancer is estimated to be 1 in every 6 men [1]. With early detection strategies, over 80 % of men with prostate cancer are diagnosed with localized disease, undergo treatment, and are either cured of their prostate cancer or they live many years after the prostate cancer diagnosis. Prostate cancer is responsible for only 10 % of all cancer deaths; hence, most men with prostate cancer die “with” their cancer, rather than “of” their prostate cancer. In the Western World, the median age at prostate cancer diagnosis is 66 years, while the median age at dying of prostate cancer is 80 years. So, among men with prostate cancer, attention for quality-of-life issues and particularly sexual activity is of paramount importance [2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Frey A, Sonksen J, Jakobsen H, et al. Prevalence and predicting factors for commonly neglected sexual side effects to radical prostatectomies: results from a cross-sectional questionnaire-based study. J Sex Med. 2014;11:2318–26.
SEER cancer statistics factsheets: prostate cancer. National Cancer Institute. Bethesda, MD. 2015. Available from: http://seer.cancer.gov/statfacts/html/prost.html.
Klein T, Palisaar RJ, Holz A, et al. The impact of prostate biopsy and periprostatic nerve block on erectile and voiding function: a prospective study. J Urol. 2010;184:1447–52.
Helfand BT, Glaser AP, Rimar K, et al. Prostate cancer diagnosis is associated with an increased risk of erectile dysfunction after prostate biopsy. BJU Int. 2013;111:38–43.
Incrocci L, Madalinska JB, Essink-Bot ML, et al. Sexual functioning in patients with localized prostate cancer awaiting treatment. J Sex Marital Ther. 2001;27:353–63.
Tal R, Alphs HH, Krebs P, et al. Erectile function recovery rate after radical prostatectomy: a meta-analysis. J Sex Med. 2009;6:2538–46.
Nelson CJ, Scardino PT, Eastham JA, et al. Back to baseline: erectile function recovery after radical prostatectomy from the patients’ perspective. J Sex Med. 2013;10:1636–43.
Montorsi F, McCullough A. Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. J Sex Med. 2005;2:658–67.
Berookhim BM, Nelson CJ, Kunzel B, et al. Prospective analysis of penile length changes after radical prostatectomy. BJU Int. 2014;113(5b):E131–6.
Nelson CJ, Lacey S, Kenowitz J, et al. Men’s experience with penile rehabilitation following radical prostatectomy: a qualitative study with the goal of informing a therapeutic intervention. Psychooncology. 2015;24:1646–54.
Incrocci L. Sexual function after external-beam radiotherapy for prostate cancer: what do we know? Crit Rev Oncol Hematol. 2006;57:165–73.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Tal, R. (2017). Prostate Cancer. In: Reisman, Y., Gianotten, W. (eds) Cancer, Intimacy and Sexuality. Springer, Cham. https://doi.org/10.1007/978-3-319-43193-2_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-43193-2_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43191-8
Online ISBN: 978-3-319-43193-2
eBook Packages: MedicineMedicine (R0)